Monthly Archives: July 2016

Alta Vista Welcomes Richard Groome as Director of Corporate Finance and Global Business Development

VANCOUVER, BC / ACCESSWIRE / July 18, 2016 / Alta Vista Ventures (AVV-CSE) is pleased to announce that Richard Groome has joined the Company as Director of Corporate Finance and Global Business Development.

Mr. Groome is an entrepreneur who started two successful securities firms in the 80’s and 90’s. Mr. Groome has the reputation of being one of the preeminent financiers of small and medium sized emerging growth companies. He has actively managed or participated in over 400 financings representing some $4 billion of small cap deals and is very well versed in start-up and early stage ventures.

Prior to the founding of Notre Dame Capital, Mr. Groome was a co-founder of Marleau Lemire Inc., which became the number one firm in Canada in small, mid cap financing during the late 1980’s. He followed up that success with the creation of Groome Capital Inc, where he developed Canada’s leading underwriter of IPO’s, Private Placements and Secondary offerings on the internet between 1998 and 2000. Groome Capital was subsequently sold to Desjardins Group in 2001, Canada’s seventh largest financial institution at the time. Mr. Groome was also a director of the CDNX Exchange, the predecessor of the TSX Venture exchange in addition to serving on the Board of Directors of numerous public and private companies over the last 30 years.

“The plan for Alta Vista is indeed ambitious and very exciting. I am very happy to be involved on the ground floor of this unique situation in the Unmanned Aerial Vehicle industry. It is very clear the industry is currently experiencing substantial growth and new uses are being discovered all the time,” said Mr. Groome.

Mr. Groome has been granted 500,000 stock options at $0.10.

About Alta Vista Ventures:

Alta Vista Ventures’ goal is to enter the Unmanned Aerial Vehicle (UAV) industry by purchasing a varied group of companies that will complement each other and, in turn, create a consortium of businesses that will cover all aspects of the UAV industry.

On behalf of the Board,

“Jason Springett”
Jason Springett
President

For additional information on Alta Vista Ventures please contact Mr. Donald Shaxon at 289-697-8625.

Neither Canadian Securities Exchange (CSE) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements in this press release, other than purely historical information, including statements relating to the Company’s future plans and objectives or expected results, may include forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in resource exploration and development. As a result, actual results may vary materially from those described in the forward-looking statements.

SOURCE: Alta Vista Ventures Ltd.

ReleaseID: 442512

Gotta Read It All: EduMuch Launches Pokemon Go Series

EduMuch has launched a five-part series covering the ins and outs of the new mobile gaming phenomenon, Pokemon Go.

Gotta Read It All: EduMuch Launches Pokemon Go Series

Lakewood, USA – July 18, 2016 /PressCable/

By popular demand, EduMuch has announced and launched a mini-series of features designed to cover the ins and outs of the new worldwide mobile gaming phenomenon, Pokemon Go. Developed by Niantic, Pokemon Go has become the most talked about mobile game ever, taking the world by storm and capturing the attention of millions. Featuring articles such as “What is Pokemon Go? Nintendo’s New Mobile Gaming Phenomenon Explained”, “How to Play Pokemon Go: A Beginners Guide“, “Top 10 Tricks and Secrets in Pokemon Go”, “Pokemon Go Review 2016 – Is It Really Just A Fad?”, and “Top 10 Ways Niantic Can Improve Pokemon Go”, EduMuch has covered Pokemon Go from all angles, providing readers with the most comprehensive gaming background possible.

The Pokemon Go phenomenon has truly reached previously untouched heights – having surpassed Twitter in active users and Tinder in downloads, Pokemon Go is now the biggest mobile game in history. Demand for information, how-to’s and strategy for the game is at an all-time high, and EduMuch has decided to step up and fill the gap, creating useful and practical pieces of content for gamers of all skill levels. EduMuch has made previous ventures into the gaming category but this represents the most significant series that has been produced – a full-fledged breakdown of all things Pokemon Go, at the height of its popularity.

By providing readers with information on what Pokemon Go is, how to play it, a full and comprehensive review, and tips and secrets, EduMuch is responding to widespread demand for more gaming content on the internet.

About The Company

EduMuch produces educational content as well as gaming and fitness features in an attempt to bring readers the latest in various lifestyles. EduMuch also produces content on technological education as well as the latest in wearable fitness tech, educational trends, and more – making it a multi-purpose blog.

Learn More at EduMuch.com

For more information, please visit https://www.edumuch.com/

Contact Info:
Name: Nate M
Organization: EduMuch

Release ID: 123884

LED Medical Diagnostics Announces Preliminary Q2 2016 Financial Results

VANCOUVER, BC / ACCESSWIRE / July 18, 2016 / LED Medical Diagnostics Inc. (“LED Medical” or the “Company”) is pleased to announce today that preliminary revenue numbers for the quarter ending June 30, 2016 are $3.7 million, as measured in US$, representing an approximate 12% increase over the prior year period of $3.3 million. The Company’s revenue for the six-month period ended June 30, 2016 was $5.8 million, representing a year-over-year increase as compared to the $5.7 million result from the first half of 2015. These revenue results are preliminary only and subject to finalization by the Company.

“Our experienced team continues to execute at a high-level, delivering solid growth in the second quarter after a softer beginning to 2016 in Q1,” stated Dr. David Gane, Chief Executive Officer of LED Medical. “We continue to experience expansion of our customer base as a result of our next-generation imaging solutions combined with white-glove customer service. More than ever, LED is establishing itself as a premium provider in this space and we anticipate carrying our sales momentum into the balance of 2016.”

For more information, please visit www.leddental.com.

About LED Medical Diagnostics Inc.

Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc., through its wholly-owned subsidiaries LED Dental Inc. and LED Dental Ltd, provide dentists and oral health specialists with advanced diagnostic imaging products and software, in addition to the award-winning VELscope® Vx tissue fluorescence visualization technology. Backed by an experienced leadership team and dedicated to a higher level of service and support, LED Dental is committed to providing dental practitioners with the best technology available by identifying and adding leading products to its growing portfolio.

The Company is currently listed on the TSX Venture Exchange (TSX-V) under the symbol “LMD”, the OTCQX under the symbol “LEDIF”, as well as the Frankfurt Stock Exchange under the symbol “LME”. For more information, call 844.952.7327 or visit www.leddental.com/investor-relations.

LED Medical Diagnostics

Investor Relations:
Bristol Capital
Glen Akselrod
Phone: 905.326.1888, ext. 10
Email: glen@bristolir.com

Media Contact:

LED Dental
Chris Koch
Phone: 678.293.9413
Email: chris.koch@leddental.com

Corporate Contact:

LED Medical
David Gane, CEO
Phone: 604-434-4614 x227
Email: david.gane@leddental.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Such forward-looking statements or information include statements regarding, but not limited to the Company’s future growth strategy, its distribution strategy and product offerings, potential expansion of the Company’s technology to other medical applications or markets, or the potential introduction of new technologies by the Company. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation’s actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to competition risks, distributor risks, product development risks such as regulatory, design, intellectual property and other factors described in the Corporation’s reports filed on SEDAR including its Annual Information Form and financial report for the year ended December 31, 2015. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: LED Medical Diagnostics Inc.

ReleaseID: 442467

China Xiniya Fashion Limited Announces Share Transfer Transaction

XIAMEN, FUJIAN, CHINA / ACCESSWIRE / July 18, 2016 / China Xiniya Fashion Limited (“Xiniya” or the “Company”) (NYSE:XNY), a leading provider of men’s business casual apparel in China, today announced that the Company’s controlling shareholder, Qiming Investment Limited, a British Virgin Islands company (the “Seller”) controlled by the Company’s Chairman and Chief Executive Officer, Qiming Xu, entered into an agreement to sell a controlling interest in the Company (the “Agreement”) to Perfect Lead International Limited and Honest Plus Investments Limited, both British Virgin Islands companies (collectively the “Purchasers”) on July 17, 2016.

As of the date of the Agreement, the Seller beneficially owns 134,359,960 ordinary shares of the Company, accounting for approximately 59% of the total outstanding shares of the Company. Pursuant to the Agreement, the Seller will sell 114,996,929 ordinary shares of the Company (the “Seller Shares”), or 50.5% of the total outstanding shares of the Company, to the Purchasers, for an aggregate purchase price of RMB86,426,661 (US$12,937,155), or RMB0.75 per ordinary share (or US$1.80 per ADS), which is approximately 172.57% of the volume weighted average closing price of the shares for the fifteen (15) trading days prior to and including July 15, 2016.

The closing of the above-mentioned share transfer requires, among other conditions, the following to occur first: (1) the Company’s board of directors and shareholders must approve the sale of Xiniya Holdings Limited, the Company’s wholly owned subsidiary in Hong Kong, to Mr. Qiming Xu or his designees at a price to be determined by an independent third party valuer (the “Xiniya Transaction”); and (2) the Company must take such corporate actions as are necessary to approve the acquisition of True Silver Limited (“True Silver”), a British Virgin Islands company, which will utilize a variable interest entity (VIE) structure to operate and consolidate 70% of the financial results of Hubei Chutian Lending Company, Ltd. (“Chutian”), a PRC company engaged in the lending of small loans to customers in China, at a price to be determined by an independent third party valuer (the “Chutian Transaction”). True Silver is wholly-owned by Honest Plus Investments Limited and indirectly controlled by Wei Qizhi who is the controlling shareholder of each of the Purchasers and the founder of Chutian. As a result of the Xiniya Transaction and the Chutian Transaction, the Company’s core business will be changed from men’s fashion to lending, which will be expanded to broader financial services in the future. In addition, the Purchasers’ designees will be appointed as directors of the board, Chairman and Chief Executive Officer of the Company to be effective immediately after the closing.

The Seller and Purchasers also simultaneously entered into a voting agreement and irrevocable proxy, pursuant to which the Seller appoints the Purchasers as proxies authorized to vote all of the Seller Shares at any meeting of the shareholders of the Company and in connection with any corporate action by the shareholders of the Company related to the Xiniya Transaction and the Chutian Transaction.

The closing of the purchase and sale of the Seller Shares will occur no more than ten (10) business days after all conditions precedent to the closing have been satisfied or waived.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “going forward,” “outlook” and similar statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control, which may cause the Company’s actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

About China Xiniya Fashion Limited

Xiniya is a leading provider of men’s business casual apparel in China. The Company designs men’s business casual and business formal apparel and accessories, which are marketed under the Xiniya brand, and sells through its distribution and retail network that includes 21 distributors and authorized retail outlets. Its products are sold to consumers at over 300 authorized retail outlets owned and managed by third parties located in 20 provinces, four autonomous regions, and four municipalities in China. This retail network focuses on second and lower-tier cities, where increasing affluence has led to an improvement in living standards and where most international men’s apparel brands do not have a significant presence. The Company’s target consumers are male working professionals in China between the ages of 25 and 45 who seek fashionable clothing to suit their working and lifestyle needs. For more information, please visit the Company’s website at http://www.xiniya.com.

For additional information, please contact:

China Xiniya Fashion Limited
Mr. Chee Jiong Ng
Chief Financial Officer
Telephone: +86 1365 5939 932
Email: ngcheejiong@xiniya.com

SOURCE: China Xiniya Fashion Limited

ReleaseID: 442506

Pearlescent Pigment Market Will Maintain Growth At 4.4% CAGR Till 2022: Grand View Research, Inc.

According to report published by Grand View Research, Inc, global pearlescent pigment market demand is expected to reach 233.2 kilo tons by 2022, revenue will reach $1.92 billion by 2022. Enhanced demand from automotive and construction sectors to drive market growth.

Pearlescent Pigment Market Will Maintain Growth At 4.4% CAGR Till 2022: Grand View Research, Inc.

San Francisco, California, United States – July 18, 2016 /MarketersMedia/

The global pearlescent pigment market is expected to reach USD 1.92 billion by 2022, according to a new report by Grand View Research, Inc. Growing demand for high performance, high brilliance paints on account of expanding automotive & construction industries particularly in Asia Pacific and the Middle East is expected to remain a key driving factor for the global market.

The shift in trend towards reducing VOC emissions and growing awareness regarding sustainability is also a vital determinant for the market growth. Developed markets are anticipated to face obstacles in the form of stringent regulatory norms, hampering market growth over the forecast period.

Titanium dioxide (TiO2) coated mica pigment was the leading product segment and accounted for 35.9% of total market volume in 2014. Increasing penetration of these pigments in automotive, construction, printing inks and other major end-use industries is expected to fuel the demand. Good hiding power, high luster & brilliance, coupled with compatibility to several materials is expected to boost the segment over the forecast period.

Access Full Research Report: http://www.grandviewresearch.com/industry-analysis/pearlescent-pigment-market

Key findings:

• Global pearlescent pigment market demand was 174.8 kilo tons in 2014 and is expected to reach 233.2 kilo tons by 2022, growing at a CAGR of 4.4%from 2015 to 2022
• Iron/ferric oxide-mica pigment is also expected to witness significant growth on account its high refractive index, metallic luster, excellent hiding properties and weather resistance. Increasing application in the cosmetics and printing inks sector is a major driving force for the product.
• Automotive paints and industrial coatings emerged as the leading application segment and accounted for 34.1% of global market in 2014. Increasing consumer preference for high-value coatings and colorful iridescence on sports and luxury vehicles is likely to foster the market growth.
• North America was the leading pearlescent pigment consumer and accounted for 38.2% of total market volume in 2014. Asia Pacific is expected to witness the highest growth of 4.9% from 2015 to 2022.Rapid industrialization and expansion of major end-use industries such as automotive and construction in Thailand, India, China and Indonesia are expected to drive the regional market.
• Global pearlescent pigment industry is fragmented with the presence of several major multinationals and regional companies across the globe. Key participants in the industry include BASF SA, Sun Chemical Performance Pigments, Merck Performance Materials, Huaian Concord Industrial Products Co. Ltd., Lansco Colors, L’Arca Srl., Fujian Kuncai Fine Chemicals Co. Ltd., RIKA Technology Co. Ltd and Smarol Technology Co. Ltd.
Grand View Research has segmented the pearlescent pigment market on the basis of product, application and region:

Request for free sample of this research report: http://www.grandviewresearch.com/industry-analysis/pearlescent-pigment-market/request

Market Segmentation:

Global IVF Procedures Outlook (Revenue, USD Million, 2012 – 2022)
• Intracytoplasmic Sperm Injection (ICSI)
• Frozen Embryo Replacement (FER)
• Pre-implantation Genetic Diagnosis (PGD)
• Others
Global IVF Types of Cycles Outlook (Revenue, USD Million, 2012 – 2022)
• Fresh Donor
• Frozen Donor
• Fresh Non-donor
• Frozen Non-donor
Global IVF Instruments Outlook (Revenue, USD Million, 2012 – 2022)
• IVD Disposable Devices
• Culture Media
• Capital Equipment
IVF Regional Outlook (Revenue, USD Million, 2012 – 2022)
• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Rest of Europe
• Asia Pacific
• India
• Japan
• China
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• MEA
• South Africa
• Rest of MEA

Access press release of this research report: http://www.grandviewresearch.com/press-release/global-pearlescent-pigment-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services.

For more information, please visit http://www.grandviewresearch.com

Contact Info:
Name: Sherry James
Email: sales@grandviewresearch.com
Organization: Grand View Research, Inc.
Address: 28 2nd Street, Suite 3036, San Francisco, California, 94105
Phone: 1-415-349-0058

Source: http://marketersmedia.com/pearlescent-pigment-market-will-maintain-growth-at-4-4-cagr-till-2022-grand-view-research-inc/123878

Release ID: 123878

IVF Market To Grow Exponentially With Increase In Number Of Fertility Related Issues Caused By Irregular Lifestyle Till 2022

According to report published by Grand View Research, Inc, global IVF (in vitro fertilization) market is expected to grow at 11.7% CAGR till 2022, competitive pricing of procedures is expected to augment market growth.

IVF Market To Grow Exponentially With Increase In Number Of Fertility Related Issues Caused By Irregular Lifestyle Till 2022

San Francisco, California, United States – July 18, 2016 /MarketersMedia/

Global In-Vitro Fertilization (IVF) market is expected to reach USD 27 billion by 2022, according to a new report by Grand View Research, Inc. The market is driven by the increasing incidence of infertility owing to, lifestyle changes, expansion of fertility procedures for treating male infertility such as ICSI, government initiatives to provide better reimbursement policies, and continuous efforts by the industry contributors.

Moreover, the availability of genomic testing enabling the prevention of the transfer of genetic disease during IVF use is further expected to drive the market demand. The increase in the number of IVF treatment has led more insurance players to cover the IVF procedures. This has ultimately led to competitive pricing and has moderated the treatment costs as IVF has been a successfully practiced technology. This will most likely drive the market by introducing treatment standardization and automation.

The behavioral shift in the society is a major factor contributing to the decreased Total Fertility Rate (TFR). These factors include an increasing number of women in the labor force, the increased age of the first birth, a shift from rural to urban societies, lower marriage rates, postponement of marriage, and greater levels of education for women.

Obesity is another factor, which has led to an increase in infertility in the population. This is due to the fact that the fat deposited on women’s abdomen prevents follicular stimulation and produces male hormones. In the case of males, the rising fat decreases testosterone levels causing a problem in sperm production. Doctors have started recommending weight loss in men prior to fertility treatments along with proper Body Mass Index (BMI) maintenance. The U.S. Endocrine Society has established the use of Letrozole to increase the testosterone levels in obese patients.

Access Full Research Report: http://www.grandviewresearch.com/industry-analysis/in-vitro-fertilization-market

Key findings:

• Intracytoplasmic Sperm Injection (ICSI) dominated the market in 2014.ICSI was introduced in the year 1992 and boosted the fertility rates from 50% to 80%, according to the American Society for Reproductive Medicine. In April 2016, Nigeria recorded its first successful delivery from a frozen egg. Bridge Clinic has stored the eggs using the flash-freezing technique. With this birth, Nigeria has put itself on the global map as it now offers IVF through frozen eggs. The eggs were then fertilized using the ICSI technique.
• Frozen Embryo Replacement (FER) technique is expected to witness a rapid rise in demand. Conventionally, most embryos were transferred through fresh cycles. However, with technology refinement, the number of frozen embryo transfers and the success rates has increased. Moreover, the policy of freezing the embryos has also reduced the chances of ovarian hyper-stimulation. The frozen embryo transfers enable single egg transfer, thus, giving enough time for the endometrial layer to heal from the medicine stimulation effect. This ensures higher success rates.
• Culture media dominated the overall market in terms of revenue in 2014. With the increasing government funding and industrial support for employees for egg/sperm freezing, the demand for cryopreservation and the needed media for it is expected to witness growth. There has been an increase in the research activities undertaken to improve the culture media and to procure maximum boar sperms or eggs, spurring market growth. Moreover, the increasing number of egg/sperm donor banks is expected to drive the demand for sperm, egg, and embryo processing media during the forecast period.

Request for free sample of this research report: http://www.grandviewresearch.com/industry-analysis/in-vitro-fertilization-market/request

Market Segmentation:

IVF Procedures Outlook (Revenue, USD Million, 2012 – 2022)
• Intracytoplasmic Sperm Injection (ICSI)
• Frozen Embryo Replacement (FER)
• Pre-implantation Genetic Diagnosis (PGD)
• Others
IVF Types of Cycles Outlook (Revenue, USD Million, 2012 – 2022)
• Fresh Donor
• Frozen Donor
• Fresh Non-donor
• Frozen Non-donor
IVF Instruments Outlook (Revenue, USD Million, 2012 – 2022)
• IVD Disposable Devices
• Culture Media
• Capital Equipment
IVF Regional Outlook (Revenue, USD Million, 2012 – 2022)
• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Rest of Europe
• Asia Pacific
• India
• Japan
• China
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• MEA
• South Africa
• Rest of MEA

Access press release of this research report: http://www.grandviewresearch.com/press-release/global-ivf-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services.

For more information, please visit http://www.grandviewresearch.com

Contact Info:
Name: Sherry James
Email: sales@grandviewresearch.com
Organization: Grand View Research, Inc.
Address: 28 2nd Street, Suite 3036, San Francisco, California, 94105
Phone: 1-415-349-0058

Source: http://marketersmedia.com/ivf-market-to-grow-exponentially-with-increase-in-number-of-fertility-related-issues-caused-by-irregular-lifestyle-till-2022/123880

Release ID: 123880

Vatic Ventures Corp. is Back

ZURICH, SWITZERLAND / ACCESSWIRE / July 18, 2016 / Today, Stephan Bogner from Rockstone Research published an initiating coverage on Vatic Ventures Corp. (TSX.V: VCV.H) as on July 12 the company has filed with the TSX Venture Exchange the preliminary documents required for the approval of the acquisition of 80% of Saksrithai Development Co. Ltd.

As a result of filing the preliminary documents together with its annual financial statements with various applicable securities commissions, the company’s cease trade order has been revoked and its shares have been reinstated for trading effective July 14.

Rockstone is starting to follow Vatic’s corporate developments and will report, once materialized, more details on its intent to acquire 80% of the issued and outstanding shares of Saksrithai Development Co. Ltd., a Thailand company holding 2 Special Prospecting Licences (“SPL”) for the exploration of potash in northern Thailand’s prolific Khorat Basin, which contains a relatively large evaporate basin of Cretaceous age. The Dan Khun Thot Project from Thai Kali Ltd. is located adjacent to, and contiguous with Saksrithai’s licence area which Vatic intends to acquire. Dan Khun Thot’s initial mineable reserve has been estimated to be 103 million t at an average potash grade of 21.5% KCl. Both sylvinite (up to 5 m thick) and carnallite (up to 60 m thick) are present in drill holes.

The full report can be accessed with the following links:

English (PDF):

http://rockstone-research.com/images/PDF/Vatic1en.pdf

English (web version):

http://rockstone-research.com/index.php/en/research-reports/1251-Vatic-Ventures-is-back

German (PDF):

http://rockstone-research.com/images/PDF/Vatic1de.pdf

Disclaimer:
Please read the full disclaimer within the full research report as a PDF as
fundamental risks and conflicts of interest exist.

SOURCE: Rockstone Research

ReleaseID: 442501

Oxis International to Hold Investor Conference Call

LOS ANGELES, CA / ACCESSWIRE / July 18, 2016 / Oxis International Inc. (OTC: OXIS and OXI.PA), a biotechnology company focused on immunotherapies for the treatment of cancer, is pleased to announce that the company will be holding an investor conference call on Thursday July 21, 2016 at 4:30PM EST.

The call will be hosted by BiotechStocks.com and company CEO Mr. Anthony Cataldo in preparation for a strong second half of 2016 after making large strides during the first two quarters of the year. Mr. Cataldo stated, “We are very optimistic for the outlook on the rest of this year. After the success we’ve seen already from our initial trials of OXS-1550, we feel that the future is looking bright. We are excited to be hosting our first investor conference call of the year to go over everything we’ve already gotten underway as well as what we plan to achieve before 2017. We’re happy to have the team at Biotech Stock host this important call and will be looking forward to all questions we’ll address during the call.”

For those interested in attending the conference call and/or submitting questions, please refer to the following information:

Dial-in Number: 712.775.7031
Meeting ID Number: 576-591-822

Please direct all questions to oxis@biotechstocks.com. All questions should be submitted before 12PM EST on Thursday, July 21, 2016.

ABOUT OXIS INTERNATIONAL, INC.

Oxis International, Inc., through a wholly owned subsidiary, Oxis Biotech, Inc., develops innovative drugs focused on the treatment of cancer and other unmet medical needs. Oxis’ lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 simultaneously targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug’s cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS’ lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.

About Biotech Stocks (www.BiotechStocks.com)

Biotech Stocks (www.biotechstocks.com) is your best resource for today’s emerging biotech industry. Whether you’re looking for the best biotech stocks to buy, biotech news, trends in biotech, articles within the biotech industry and so much more, BiotechStocks.com is your destination for it all. Our goal is to become the central hub for all who are seeking current Biotech Stock News as well as biotech industry, political and social news, articles, trends & overall insight, delivered in a way that we all can relate to.

FORWARD LOOKING STATEMENTS:

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company’s ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company website: OXIS.COM

SOURCE: Oxis International, Inc.

ReleaseID: 442484

VL Health Announces the Launch of their Newly Updated and Improved Website

The Recently Revised Website Includes the Addition of New Products and Better Graphics on the Homepage

LOS ANGELES, CA / ACCESSWIRE / July 18, 2016 / VL Health, a top producer of quality health and beauty products, is pleased to announce the launch of its new and updated website. At the recently renovated online VL Health Shop, customers will find an enhanced selection of products, improved graphics on the homepage, special offers and expedited shipping options.

In addition to the upgraded website, the founders of VL Health are also celebrating a positive review of their company on the Suplementos.org website. The authors reviewing the VL Health product line took an in-depth look at Arizona-based company and its diverse selection of products.

As the review notes, VL Health sells a nice selection of skin care products, including one called Celleral Eye Gel. The cosmetic cream was designed to reduce the signs of aging around the eyes.

“More specifically, it minimizes the appearance of fine lines, reducing puffiness/bags under the eyes, and giving the eyes a firmer and brighter look,” noted the review on Suplementos.org, adding that the product contains some effective skin care ingredients such as Pronalen Fruit Acids, DuPont Glypure, Syn-Coll and Regu-Age.

Celleral Anti-Aging Serum is another product found on the VL Health site. As the review notes, it is meant to enhance skin health and combat the signs of aging. Argan Oil, which is extracted from the argan tree in Morocco, is also sold on the VL Health website. As the review notes, many people who use pure argan oil on their skin are pleased how it naturally moisturizes their dry skin, leaving it looking healthy and vibrant.

“In addition to offering great products, VL Health also believes in offering clients value for the money as well as a great customer experience,” the review noted.

“For instance, on the customer service front, VL Health has posted an email address and phone number on its site that customers can use to order its products or make queries.”

The review also noted the way VL Health rewards its customers; for example, with a buy 2, get 1 free special and through offering lower prices on 3-packs of argan oil.

Anybody who would like to learn more about VL Health is welcome to visit the company’s updated and more user-friendly website at any time. There, if they wish, they may also place an order.

About VL Health:

VL Health is a leader in producing beauty and health products. For more details go to their website to learn more about all the company has to offer. Website: http://www.vlhealth.com/.

Contact:

Rex Huff
admin@rocketfactor.com
(949) 555-2861


SOURCE:
VL Health

ReleaseID: 442477

Diabetes Devices Market To Witness Enhanced Usage In Minimally Invasive Diagnostic Applications Till 2024: Grand View Research, Inc.

According to report published by Grand View Research, Inc. , global diabetes devices market revenue is expected to reach $35.5 billion by 2024, rising awareness with regard to technologically advanced monitoring tools, such as the continuous glucose monitor, is expected to augment market growth.

Diabetes Devices Market To Witness Enhanced Usage In Minimally Invasive Diagnostic Applications Till 2024: Grand View Research, Inc.

San Francisco, California, United States – July 18, 2016 /MarketersMedia/

The global diabetes devices market is expected to reach USD 35.5 billion by the year 2024, according to a new report published by Grand View Research, Inc. Major drivers of the market include the growing number of diabetic patients owing to the sedentary lifestyles and unhealthy food habits. The growing demand for the advanced and minimally invasive, diagnostic as well as monitoring devices is expected to propel the market growth during the forecast period.

The rising awareness with regard to the technologically advanced monitoring tools, such as the continuous glucose monitor, is a crucial factor expected to spur the growth of the market. The demand for affordable monitoring devices in the developed as well as the less-developed countries is expected to propel the market growth of products, such as glucose test strips.

The existence of relatively smooth product approval procedures in most of the developed countries including the U.S and European countries are expected to boost the insulin devices market. The rising popularity of the compact, easy to carry monitoring devices, and the introduction of minimally invasive, highly efficient devices is expected to drive the market growth at a lucrative rate. However, the disparity in the reimbursement policies is primarily challenging the overall growth of this market.

Access full research report: http://www.grandviewresearch.com/industry-analysis/diabetes-devices-market

Key findings

• The demand for the diabetes devices is expected to surge owing to the factors such as the constantly increasing geriatric population prone to diabetes, the government initiatives taken to support better management of diabetes, and the growing awareness regarding diabetes devices
• In 2015, the test-strips sub-segment captured the largest market share in the blood glucose monitoring and diagnostic devices segment. The insulin pens accounted for the largest share of the insulin delivery devices segment. The global diabetes devices market is expected to reach USD 35.4 billion in 2024.
• The monitoring and diagnostic devices segment captured the largest market share of the overall market in 2015. The segment accounted for around 71% of the total market owing to repeat purchases.
• The monitoring and diagnostic devices segment is expected to maintain its dominance during the forecast period owing to the introduction of technologically advanced products coupled with the high adoption of these products in the near future
• North America captured the largest market share of around 32% in the year 2015. The domination of the market is expected to continue with a CAGR of 5.9%. The growing diabetic population, the availability of technologically advanced devices, and the presence of skilled professionals are the factors contributing to the growth of the market in North America.
• Asia Pacific is the fastest growing segment of the market. Countries, such as China and India are expected to show a swift growth owing to the high prevalence of diabetes, the rising awareness regarding commercially available devices, and the growing disposable income in these countries
• The key players in diabetes devices market include Abbott Laboratories, Inc., Bayer Healthcare AG, Johnson& Johnson, F. Hoffmann La-Roche Ltd., Becton Dickinson and Company, Medtronic, Inc., Novo Nordisk A/S, and Sanofi.

Request for free sample of this research report: http://www.grandviewresearch.com/industry-analysis/diabetes-devices-market/request

Market Segments:

Product, revenue, (USD Million), 2013 – 2024
• Self-Monitoring and Diagnostic Devices
• Lancets
• Analogue glucose monitor
• Continuous glucose monitor
• Test Strips
• Insulin Delivery Devices
• Syringes
• Pens
• Pumps
• Injectors
Region, revenue, (USD Million), 2013 – 2024
• North America
• U.S. Diabetes Devices Market, by Device Type
• Canada Diabetes Devices Market, by Device Type
• Europe
• U.K. Diabetes Devices Market, by Device Type
• Germany Diabetes Devices Market, by Device Type
• Asia Pacific
• China Diabetes Devices Market, by Device Type
• India Diabetes Devices Market, by Device Type
• Latin America
• Brazil Diabetes Devices Market, by Device Type
• Mexico Diabetes Devices Market by Device Type
• MEA
• South Africa Diabetes Devices Market, by Devices Type

Access press release of this research report: http://www.grandviewresearch.com/press-release/global-diabetes-devices-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services.

For more information, please visit http://www.grandviewresearch.com

Contact Info:
Name: Sherry James
Email: sales@grandviewresearch.com
Organization: Grand View Research, Inc.
Address: 28 2nd Street, Suite 3036, San Francisco, California, 94105
Phone: 1-415-349-0058

Source: http://marketersmedia.com/diabetes-devices-market-to-witness-enhanced-usage-in-minimally-invasive-diagnostic-applications-till-2024-grand-view-research-inc/123873

Release ID: 123873